IGF1 and metabolic dysfunction-associated steatohepatitis: These findings are consistent with previous studies showing that plasma IGF-1 concentration is a determinant of eGFR in hypertensive individuals [19], and suggest that lower amounts of circulating IGF-1 associated with NAFLD/NASH [20], [21] could contribute to the reduced eGFR observed in individuals with high or intermediate probability of advanced liver fibrosis.